P Vang - JoVE Visualize

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Journal of Visualized Experiments : Jove|December 5, 2013

Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy developmentDaniel P Vang, Gregory T Wurz, Stephen M Griffey, et al.

Cancer Research Communications|April 20, 2026

Capturing Latino Health Disparities: Lessons from Mail- and Community-Based Population Health Surveys in CaliforniaApril P Vang, Juanita Elizabeth Quino, Angelica M Rolon, et al.

JCO Precision Oncology|May 26, 2021

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung CancerCaroline E McCoach, Aiming Yu, David R Gandara, et al.

Molecular Cancer Therapeutics|February 28, 2018

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.

Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Journal of Visualized Experiments : Jove|December 5, 2013

Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy developmentDaniel P Vang, Gregory T Wurz, Stephen M Griffey, et al.

Cancer Research Communications|April 20, 2026

Capturing Latino Health Disparities: Lessons from Mail- and Community-Based Population Health Surveys in CaliforniaApril P Vang, Juanita Elizabeth Quino, Angelica M Rolon, et al.

JCO Precision Oncology|May 26, 2021

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung CancerCaroline E McCoach, Aiming Yu, David R Gandara, et al.

Molecular Cancer Therapeutics|February 28, 2018

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.

Pageof 2